Logo image of MTP

MIDATECH PHARMA PLC-ADR (MTP) Stock Fundamental Analysis

NASDAQ:MTP - Nasdaq - US59564R5000 - ADR - Currency: USD

0.2851  -0.06 (-18.52%)

After market: 0.2801 -0.01 (-1.75%)

Fundamental Rating

1

Taking everything into account, MTP scores 1 out of 10 in our fundamental rating. MTP was compared to 571 industry peers in the Biotechnology industry. MTP has a bad profitability rating. Also its financial health evaluation is rather negative. MTP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MTP had negative earnings in the past year.
MTP had a negative operating cash flow in the past year.
MTP Yearly Net Income VS EBIT VS OCF VS FCFMTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -5M -10M -15M -20M

1.2 Ratios

MTP has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MTP Yearly ROA, ROE, ROICMTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -100 -200 -300

1.3 Margins

MTP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTP Yearly Profit, Operating, Gross MarginsMTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

MTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
MTP has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, MTP has a worse debt to assets ratio.
MTP Yearly Shares OutstandingMTP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M
MTP Yearly Total Debt VS Total AssetsMTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -12.33, we must say that MTP is in the distress zone and has some risk of bankruptcy.
MTP's Altman-Z score of -12.33 is on the low side compared to the rest of the industry. MTP is outperformed by 81.14% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that MTP is not too dependend on debt financing.
MTP's Debt to Equity ratio of 0.07 is on the low side compared to the rest of the industry. MTP is outperformed by 62.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -12.33
ROIC/WACCN/A
WACC6.79%
MTP Yearly LT Debt VS Equity VS FCFMTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M 40M

2.3 Liquidity

MTP has a Current Ratio of 5.28. This indicates that MTP is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MTP (5.28) is comparable to the rest of the industry.
MTP has a Quick Ratio of 5.28. This indicates that MTP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MTP (5.28) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.28
Quick Ratio 5.28
MTP Yearly Current Assets VS Current LiabilitesMTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

MTP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.43%, which is quite impressive.
The Revenue has grown by 11.98% in the past year. This is quite good.
Measured over the past years, MTP shows a very negative growth in Revenue. The Revenue has been decreasing by -15.26% on average per year.
EPS 1Y (TTM)58.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.63%
Revenue 1Y (TTM)11.98%
Revenue growth 3Y-33.19%
Revenue growth 5Y-15.26%
Sales Q2Q%16.71%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTP Yearly Revenue VS EstimatesMTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M
MTP Yearly EPS VS EstimatesMTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MTP. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTP Price Earnings VS Forward Price EarningsMTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTP Per share dataMTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MTP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIDATECH PHARMA PLC-ADR

NASDAQ:MTP (3/24/2023, 8:00:00 PM)

After market: 0.2801 -0.01 (-1.75%)

0.2851

-0.06 (-18.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)04-24 2023-04-24
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.98M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.48
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.21
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.15
OCFYN/A
SpS0.12
BVpS1.34
TBVpS1.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.39%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.28
Quick Ratio 5.28
Altman-Z -12.33
F-Score2
WACC6.79%
ROIC/WACCN/A
Cap/Depr(3y)40.47%
Cap/Depr(5y)39.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.63%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.98%
Revenue growth 3Y-33.19%
Revenue growth 5Y-15.26%
Sales Q2Q%16.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.58%
OCF growth 3YN/A
OCF growth 5YN/A